Does pravastatin therapy affect cardiac enzyme levels after percutaneous coronary intervention?

Advances in Therapy

Volumn 24, Issue 3, 2007, Pages 493-504

  Bozbas, Huseyin ^a   Yildirir, Aylin ^a   Mermer, Serdar ^a   Konas, Didem ^a   Atar, Ilyas ^a   Aydinalp, Alp ^a   Ozin, Bulent ^a   Korkmaz, Mehmet E ^a   Muderrisoglu, Haldun ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Cardiac enzymes; Percutaneous coronary intervention; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEART ENZYME; NITRIC ACID DERIVATIVE; PRAVASTATIN; TROPONIN I;

ADULT; AGED; ARTICLE; BALLOON; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DRUG DOSE COMPARISON; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOMYOPATHIES; CREATINE KINASE, MB FORM; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRAVASTATIN; PREMEDICATION; TROPONIN I;

EID: 34548074993     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02848771     Document Type: Article

References (44)

1. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation. 1996;94:1528-1536.
2. Brener SJ, Ellis SG, Schneider J, Topol EJ. Frequency and long term impact of myonecrosis after coronary stenting. Eur Heart J. 2002;23:869-876.
3. Klein LW, Kramer BL, Howard E, Lesch M. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol. 1991;17:621-626.
4. Nallamothu BK, Bates ER. Periprocedural myocardial infarction and mortality: causality versus association. J Am Coll Cardiol. 2003;42:1406-1411.
5. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA Study. Circulation. 2004;110:674-678.
6. Brener SJ, Lytle BW, Schneider JP, Ellis SG, Topol EJ. Association between CK-MB elevation after percutaneous or surgical revascularization and three year mortality. J Am Coll Cardiol. 2002;40: 1961-1967.
7. Akkerhuis KM, Alexander JH, Tardiff BE, et al. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events differ? Circulation. 2002;105:554-556.
8. Kini AS, Lee P, Marmur JD, et al. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol. 2004;93: 18-23.
9. Fuchs S, Kornowski R, Mehran R, et al. Prognostic value of cardiac troponin I levels following catheter-based coronary interventions. Am J Cardiol. 2000;85:1077-1082.
10. Bertinchant JP, Polge A, Ledermann B, et al. Relation of minor cardiac troponin elevation to late cardiac events after uncomplicated elective successful percutaneous transluminal coronary angioplasty for angina pectoris. Am J Cardiol. 1999;84:51-57.
11. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 2002;105:691-696.
12. Ellis SG, Chew D, Chan A, Whitlow PL, Schneider JP, Topol EJ. Death following creatine kinase-MB elevation after coronary intervention. Circulation. 2002;106:1205-1210.
13. Herrmann J, Lerman A, Baumgart D, et al. Preprocedural statin medication reduces the extent of periprocedural non-Q wave myocardial infarction. Circulation. 2002;106:2180-2183.
14. Talazs H, Genser N, Mair J, et al. Side-branch occlusion during percutaneous transluminal coronary angioplasty. Lancet. 1992;339:1380-1382.
15. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241-251.
16. Nageh T, Sherwood RA, Harris BM, Byrne JA, Thomas MR. Cardiac troponin T and I and creatine kinase MB as markers of myocardial injury and predictors of outcome following percutaneous coronary intervention. Int J Cardiol. 2003;92:285-293.
17. Tardiff BE, Califf RM, Tcheng JE, et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. J Am Coll Cardiol. 1999;33:88-96.
18. Kugelmass AD, Cohen DJ, Moscucci M, et al. Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol. 1994;74:748-754.
19. Garbarz E, Iung B, Lefevre G, et al. Frequency and prognostic value of cardiac troponin I elevation after coronary stenting. Am J Cardiol. 1999;84:515-518.
20. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000;101:570-580.
21. Ghazzal Z, Ashfaq S, Morris DC, et al. Prognostic implication of creatine kinase release after elective percutaneous coronary intervention in the pre-IIb/IIIa antagonist era. Am Heart J. 2003; 145:1006-1012.
22. Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol. 2003;42: 1406-1411.
23. Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete micro-infarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation. 2001;103:2780-2783.
24. Herrmann J, Von Birgelen C, Haude M, et al. Prognostic implication of cardiac troponin T increase following stent implantation. Heart. 2002;87:549-553.
25. Ricciardi MJ, Davidson CJ, Gubernikoff G, et al. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J. 2003;145:522-528.
26. Cantor WJ, Newby LK, Christenson RH, et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol. 2002;39:1738-1744.
27. Bhatt DL, Topol EJ. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcome in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation. 2005;112:906-923.
28. Erbel R, Heusch G. Coronary microembolization. J Am Coll Cardiol. 2000;36:22-24.
29. Blankenship JC, Tasissa G, O'Shea C, et al. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT Trial. J Am Coll Cardiol. 2001;38:653-658.
30. Steinhubl SR, Lauer MS, Mukherjee DP, et al. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q wave myocardial infarction. J Am Coll Cardiol. 1998;32:1366-1370.
31. Sharma SK, Kini A, Marmur JD, Fuster V. Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention: benefit is extended to improvement in intermediate-term survival. Circulation. 2000;102:166-172.
32. Ellis SG, Brener SJ, Lincoff AM, et al. Beta blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise. Circulation. 2001;104:2685-2688.
33. The EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting: randomized placebo-controlled trial to assess safety of coronary stenting with use of platelet IIb/IIIa blockade. Lancet. 1998;352:87-92.
34. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized placebo-controlled trial. Lancet. 2000;356:2037-2044.
35. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol. 2004;43:1122-1126.
36. Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol. 2001;88:672-674.
37. Mulukutla SR, Marroquin OC, Smith C, et al. Effect of statin therapy prior to elective percutaneous coronary intervention on frequency of periprocedural myocardial injury. Am J Cardiol. 2004;94:1363-1366.
38. Briguori C, Colombo A, Airoldi F, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J. 2004;25:1822-1828.
39. Chang SM, Yazbek N, Lakkis NM. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv. 2004;62:193-197.
40. Gresser U, Gathof BS. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. Eur J Med Res. 2004;26:1-17.
41. Jones PH, Davidson MH, Stein EA, et al. Comparison of the Efficacy and Safety of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin Across Doses (STELLAR Trial). Am J Cardiol. 2003;92:152-160.
42. Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15: 247-251.
43. Rauch U, Osende JI, Chesebro JH, et al. Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis. 2000;153:181-189.
44. Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation. 2003;107:1750-1756.